ABM Respiratory Care Raises $14.8 Million to Advance BiWaze® Clear for Better Respiratory Health

ABM Respiratory Care Secures $14.8 Million in Funding

In a significant development for the healthcare industry, ABM Respiratory Care (ABMRC), a medical technology company committed to improving airway clearance and ventilation solutions, has announced the successful closure of its Series B financing round. This round, which raised an impressive $14.8 million, exceeded the initial target of $12 million. The funding is expected to play a crucial role in accelerating the commercialization of BiWaze® Clear, a novel airway clearance system designed for both clinical and home use.

Peter Soderberg, who serves as the Chairman of the Board for ABMRC and is also a Managing Partner at Worthy Venture Resources, led this oversubscribed funding round. His decision to double his investment reflects his confidence in the company’s progress and potential. Soderberg stated, "I was motivated to increase my ownership of ABMRC given its impressive execution to-date and the superior performance of its first two devices in treating patients across the continuum of care."

Notably, ABMRC has garnered additional support from investors such as Blue Wave Capital, LLC, which focuses on the U.S. healthcare sector. One of the co-founding partners from this investment firm has joined the ABMRC Board of Directors, underscoring the collective commitment to further innovation in respiratory care.

CEO Greg Miller remarked, "This funding represents a pivotal moment for ABM Respiratory Care, enabling us to expand access to our respiratory therapy platform and introduce transformative solutions to numerous households and healthcare facilities. We are grateful for the backing from our new and existing investors, who share our vision for intelligent, connected therapies for individuals struggling with respiratory challenges."

The BiWaze® Clear System

The funding will primarily facilitate the commercialization of BiWaze® Clear, which provides a comprehensive solution for lung health by merging three therapeutic techniques: lung expansion, high-frequency oscillations, and aerosol delivery, all integrated with a nebulizer. This compact, battery-operated device features a dual-lumen circuit that forms a portable, closed-loop system aimed at improving aerosol deposition deep within the lungs. Its design promises not only to enhance mucus clearance but also to reduce therapy times, making it more user-friendly for patients whether at home or in a hospital setting.

BiWaze® Clear is positioned to make a meaningful impact on the lives of patients, particularly those suffering from compromised respiratory health. By streamlining the therapy process, ABMRC aims to improve the overall effectiveness of respiratory treatments.

As the funding is utilized to scale U.S. sales efforts, the company is also set to invest in clinical research and enhance patient engagement through digital health capabilities. Such advancements demonstrate ABMRC’s commitment to fostering an ecosystem around supportive technologies that benefit patients worldwide.

About ABM Respiratory Care

Established with the purpose of transforming patient care, ABM Respiratory Care specializes in developing innovative and clinically differentiated respiratory solutions. The company’s connected platform aims to enhance respiratory therapy practices, leading to better oxygen exchange, reduced aerosol emission exposure, and more effective disease management for individuals with compromised respiratory systems across various care settings.

For more information on their groundbreaking technologies, visit ABM Respiratory Care. As they embark on this journey towards enhanced respiratory health, ABMRC invites all stakeholders to join in their mission, ensuring that quality care reaches those who need it most.